ADC Therapeutics SA — Form 6-K Summary
Filing date: March 3, 2022. Reporting period: fourth quarter and year ended December 31, 2021. The filing reports fourth-quarter and full-year results and business updates for the commercial-stage biotechnology company.
Financial Results and Position
| Metric | Q4 2021 | Q4 2020 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Net product revenue | $17.0 million | $0 | $33.9 million | $0 |
| Cost of product sales | $0.8 million | $0 | $1.4 million | $0 |
| Estimated gross margin | 95.5% | Not applicable | 95.9% | Not applicable |
| Research and development expense | $42.5 million | $48.6 million | $158.0 million | $142.0 million |
| Selling and marketing expense | $18.6 million | $9.4 million | $64.8 million | $22.1 million |
| General and administrative expense | $17.9 million | $20.1 million | $71.5 million | $55.1 million |
| Loss from operations | $(62.8) million | $(78.0) million | $(261.7) million | $(219.3) million |
| Net loss | $(34.4) million | $(55.9) million | $(230.0) million | $(246.3) million |
| Basic and diluted loss per share | $(0.45) | $(0.73) | $(3.00) | $(3.77) |
- Cash and cash equivalents: $466.5 million at December 31, 2021, versus $439.2 million at December 31, 2020.
- Liquidity: Total current assets were $525.2 million and current liabilities were $73.9 million, implying substantial reported current-asset coverage. Cash flow data and a formal cash runway estimate were not provided in the filing text.
- Debt and obligations: Convertible loans totaled $93.7 million, including $6.6 million current and $87.2 million long-term, excluding $37.9 million of related derivatives. The company also reported a $218.7 million deferred royalty obligation.
- Unusual items: Net loss included non-cash gains from changes in the fair value of convertible-loan derivatives of $18.6 million in Q4 and $34.9 million for the year. The company also recognized a $22.0 million quarterly and $21.5 million annual income-tax benefit related to a deferred tax asset associated with U.S. R&D tax credits and temporary differences.
Material Changes Versus Prior Period
- ZYNLONTA generated its first product revenue following its May 2021 U.S. launch: $33.9 million for 2021.
- Annual R&D expense increased 11.2%, reflecting investment in earlier-line ZYNLONTA studies, pipeline advancement, increased headcount and share-based compensation. Quarterly R&D expense declined because of lower manufacturing and chemistry-related activity after the ZYNLONTA BLA submission and approval.
- Annual selling and marketing expense increased to $64.8 million from $22.1 million due primarily to the ZYNLONTA commercial launch.
- Annual G&A expense increased to $71.5 million from $55.1 million, driven by higher headcount, share-based compensation and public-company costs.
- Annual net loss improved by $16.3 million, primarily reflecting product revenue, the derivative fair-value gain and the deferred tax benefit.
- Total liabilities increased to $451.9 million from $178.2 million, largely due to the deferred royalty obligation, increased convertible-loan balances and derivatives.
Outlook, Business Updates and Risks
- LOTIS-5, the Phase 3 confirmatory trial of ZYNLONTA plus rituximab in second-line, transplant-ineligible DLBCL, cleared its safety lead-in and began enrolling the randomized portion. Continued ZYNLONTA approval is contingent on verification and description of clinical benefit in a confirmatory trial.
- The company will discontinue the LOTIS-3 study of ZYNLONTA plus ibrutinib and will focus on the LOTIS-5 second-line opportunity.
- Management expected to initiate LOTIS-9 in first-line unfit or frail DLBCL patients in the second half of 2022 and LOTIS-7 in multiple combinations in the first half of 2022. The company will not pursue the LOTIS-8 R-CHOP dose-finding study.
- LOTIS-6 was voluntarily paused after the comparator, idelalisib, was withdrawn from the follicular lymphoma market. The company planned consultations with clinical advisors and the FDA regarding next steps.
- For camidanlumab tesirine, management expected to report topline Hodgkin lymphoma Phase 2 results in the first half of 2022 and hold a pre-BLA meeting with the FDA in the second half of 2022. The solid-tumor combination study with pembrolizumab continued dose escalation and expansion.
- The company expected to initiate the ADCT-601 Phase 1b solid-tumor combination study in the first half of 2022 and continue preclinical work supporting an IND for ADCT-212, a PSMA-targeting ADC.
- ADC Therapeutics received a $30 million upfront payment under its January 2022 exclusive Japan license for ZYNLONTA and may receive up to $205 million in additional milestones, plus royalties ranging from the high teens to low twenties on Japanese net sales.
- Key risks include clinical-trial execution, regulatory approval and confirmatory-trial requirements, commercial adoption of ZYNLONTA, pipeline safety and efficacy, competition, future financing needs and the accuracy of forward-looking development and launch timelines.
Investor Verification Items
- Verify the cash-flow statement, cash burn and projected liquidity runway, which are not included in the supplied filing text.
- Review the terms, maturity dates and potential dilution associated with the convertible loans and related derivatives.
- Assess the deferred royalty obligation and the economics of the Mitsubishi Tanabe Japan license.
- Track enrollment, interim or topline data and regulatory interactions for LOTIS-5 and the camidanlumab tesirine Hodgkin lymphoma program.
- Confirm whether planned LOTIS-7, LOTIS-9 and ADCT-601 milestones occurred on schedule and whether the ZYNLONTA confirmatory trial supports continued approval.